Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) establishes a new anti-infective research unit within the Murdoch Children’s Research Institute’s facilities in Melbourne
- The company has secured a dedicated Murdoch Children’s research team of infectious disease experts and a fit-for-purpose laboratory space to carry out its programs
- Recce says this will help support its expanding pre-clinical programs investigating the antimicrobial activity of its compounds.
- The Murdoch institute is the largest child health research institute in Australia and one of the top three worldwide for research quality and impact
- Shares in Recce are trading at 67 cents at 3:24 pm AEDT
Recce Pharmaceuticals (RCE) has established a new anti-infective research unit within the Murdoch Children’s Research Institute’s facilities in Melbourne.
As part of a research collaboration agreement, the company has secured a dedicated Murdoch Children’s research team of infectious disease experts to help carry out its pre-clinical programs and other research activities.
Further, a fit-for-purpose laboratory space with access to a library of clinical isolates and drug-resistant pathogens has been allocated solely to the facilities.
Recce said the new space would support its expanding pre-clinical programs, with infectious disease researchers dedicating their efforts to a suite of pre-clinical studies.
“With access to Murdoch Children’s world-leading facilities, this agreement will further advance our pre-clinical programs,” Recce CEO James Graham said.
“We are delighted to collaborate with Murdoch Children’s in addressing unmet medical needs and look forward to advancing anti-infective research.”
The planned research activities conducted in Recce’s AIR Unit will focus on advancing Recce’s bacterial sinusitis program, mycobacterium abscessus program and more, with all intellectual property rights and results owned by Recce.
The programs will continue to be led by Phil Sutton, the former Head of Murdoch Children’s Mucosal Immunology and Recce’s Vice President of Translational Sciences.
The company’s work with Murdoch Children’s has already played a pivotal role in the delivery of results surrounding ongoing pre-clinical programs, generating R327 data demonstrating strong bactericidal activity against a range of deadly pathogens.
Shares in Recce were trading at 67 cents at 3:24 pm AEDT.
